Navigation Links
GlySure Wins 2013 Small Business of the Year and New Product of the Year
Date:10/1/2013

OXFORD, England, October 1, 2013 /PRNewswire/ --

GlySure Limited, developer of in-hospital continuous blood glucose monitoring (CBGM) systems, today announced that it has won two major awards in the 2013 BIG (Business Intelligence Group) Awards for Business.

BIG has selected GlySure as Small Business of the Year and it also won New Product of the Year for its CBGM technology.

Business Intelligence Group's BIG Awards specialize in recognizing top performing companies and organizations. The organization's proprietary and unique scoring system selectively measures performance across multiple business domains, and rewards companies whose achievements stand above those of their peers.

"Glysure's mission and product to help control glucose levels in real time is clearly in demand," said Dawn Fordyce of the Business Intelligence Group. "With so much at stake, Glysure's continuous blood glucose monitoring system will surely save countless lives and healthcare costs."

Over two years of human use trials in over 150 intensive care unit (ICU) patients have proven that GlySure's CBGM technology can be used to continuously measure glucose levels with an extremely high degree of accuracy and repeatability across three-to-five days of a patient's stay, which is key to improving outcomes and reducing costs in the ICU. GlySure recently commenced a multi-center CE Trial on cardiac surgery patients, which the company expects to complete this fall.

"It is a great honor to be recognized by the Business Intelligence Group," said GlySure CEO Chris Jones. "This industry recognition validates the tremendous momentum we've achieved to date in delivering on the promise of Tight Glycemic Control."

About GlySure:

GlySure has developed a continuous intravascular glucose monitoring system using a proprietary optical fluorescence sensor to meet the $2B+ worldwide demand for implementation of Tight Glycemic Control (TGC) in the hospital Intensive Care Unit (ICU).  The company has demonstrated through ICU testing highly accurate sensors which can provide continuous glucose readings throughout the length of a patient's stay in the ICU. GlySure was founded in 2006, it is based in Abingdon, Oxfordshire, England and it has 30 employees. The company's products are not approved for use in the U.S. or Europe. http://www.glysure.com

Company Contact: Chris Jones, CEO, GlySure. Tel: +44(0)1235-462-870. cjones@glysure.com

Media Contact: Kara Della Vecchia, KDV Communications, Inc. Tel: +1-508-314-3127. kara@kdvcommunications.com


'/>"/>
SOURCE GlySure
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Glysure Appoints Justine McQuillan as European Director of Clinical Affairs
2. Study Demonstrates Glysure Systems Ability to Accurately Measure Blood Glucose Levels in the ICU
3. GlySure CEO to Present ICU Trial Results at Spring Medtech Industry Conferences
4. GlySure Earns ISO 13485 Certification
5. MabVax Therapeutics Receives $1,750,000 Small Business Innovation Research Contract Award From The National Cancer Institute To Support Development of Novel Pancreatic Cancer Diagnostic Imaging Agent
6. GlaxoSmithKline, Community Care of North Carolina harness "small data" to improve patient care and reduce health care costs
7. PharmaPoint: Non-Small Cell Lung Cancer - India Drug Forecast and Market Analysis to 2022
8. PDL BioPharma to Present at the 4th Annual Credit Suisse Small/Mid Cap Conference
9. Arisaph Pharmaceuticals Awarded Phase I STTR Grant To Develop Small Molecule Immune Modulators
10. Alzheimers Drug Discovery Foundation Supports Madera Biosciences to Advance Small Molecule Drugs that Upregulate apoE
11. Structure-Based Drug Design Conference in Boston, Starting June 19 PLUS These 62 Start-ups and Small Companies Will Transform Drug Delivery Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... -- Glycotope GmbH, a clinical-stage immuno-oncology company ... of Dr. Alfredo Zurlo as Chief Medical ... many years clinical experience and a proven track record ... was at Mologen AG where he was Chief Medical ... Zurlo held various positions at F Hoffmann La Roche ...
(Date:4/28/2016)...  Marking its one year anniversary since launching ... risk test, Color Genomics announced a ... impact the most common hereditary cancers affecting both ... analyzes hereditary cancer risks for breast, colorectal, melanoma, ... Color Test is physician ordered and includes genetic ...
(Date:4/28/2016)... 28, 2016 Dr. Vivek Ahuja ... and Ste phen Schmidt ... leading provider of cloud-based software solutions for life sciences, today announced ... bring a wealth of insight to a growing business.  This will ... George Phillips joined ArisGlobal in the position of ...
Breaking Medicine Technology:
(Date:4/29/2016)... York, NY (PRWEB) , ... April 29, 2016 , ... New York City based oral ... . This surgery is a very effective way to treat obstructive sleep apnea. Dr. Jamali ... , Orthognathic surgery is a procedure that involves one or both jaw bones. This surgery ...
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, the market ... funding led by Eastside Partners, with participation from existing investor Martin Ventures. ... and accelerate its technology and product roadmap. , “Jvion is experiencing ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... print media enterprise focused entirely on patients with cancer, today announced that Lynne ... chosen as the 2016 CURE® Extraordinary Healer® for Oncology Nursing , which ...
(Date:4/29/2016)... ... April 29, 2016 , ... Natren, ... animal line of probiotics, Petbiotics ™, as they fondly call them. As ... rescue groups networking for their non-profit organizations. Animal rescues across the nation face ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... awareness for Duchenne muscular dystrophy, and funding for Duchenne research, participated in the ... of the Sarepta Therapeutic’s novel Duchenne drug eteplirsen. The meeting at the Marriott ...
Breaking Medicine News(10 mins):